SEC Form 4 filed by Director White Lale

$CRDF
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $CRDF alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $CRDF alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRDF

DatePrice TargetRatingAnalyst
9/6/2024$8.00Buy
Craig Hallum
2/28/2022$26.00 → $25.00Buy
HC Wainwright & Co.
1/5/2022Outperform
William Blair
12/8/2021$19.00Outperform
Robert W. Baird
12/8/2021$19.00Outperform
Baird
8/10/2021$25.00 → $26.00Buy
HC Wainwright & Co.
8/9/2021$30.00 → $20.00Buy
Maxim Group
More analyst ratings

$CRDF
Press Releases

Fastest customizable press release news feed in the world

See more
  • Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to the World Health Organization (WHO), breast cancer cases are projected to rise by nearly 40% by 2050. Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Cardiff Oncology, Inc. (NASDAQ:CRDF

    $ALXO
    $CRDF
    $EXEL
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    - Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer ("mCRC") clinical trial (CRDF-004) - - Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors -  - Issuance of new patent with claims for the use of onvansertib for treating KRAS-mut mCRC - - Cash and equivalents of $91.7 million as of December 31, 2024, projected runway into Q1 2027 - - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cardiff Onco

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cardiff Oncology to Present at Upcoming Investor Conferences

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences. Details of the presentations can be found below. B. Riley Securities Precision Oncology & Radiopharma ConferencePresenter: Mark Erlander, CEOFormat: Panel discussion on "What It Takes to Move the Needle in Improving Responses in Colorectal Cancer"'Date: 02/28/2025Location: New York City, NY This event is for in-person participants only. Contact B. Riley for information on attending the conference.

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CRDF
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CRDF
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRDF
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRDF
SEC Filings

See more

$CRDF
Leadership Updates

Live Leadership Updates

See more
  • Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

    First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

    Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

    SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CRDF
Financials

Live finance-specific insights

See more
  • Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

    SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

    - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm - - Onvansertib was well tolerated at both doses - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - - Company will hold a conference call today at 8:00 a.m. ET / 5:00 a.m. PT - SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology co

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

    - Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2024. "This quarter has be

    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CRDF
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more